生物化模仿性纳米结构,用于针对性治疗炎症性肠病
Nature communications
|March 16, 2025
概括
这项研究引入了用于炎症性肠病 (IBD) 治疗的新型性纳米药物. 这些纳米颗粒有效地向和中和主要的炎症触发物,如脂多糖 (LPS),无细胞DNA (cfDNA) 和活性氧物种 (ROS),提供了一个有前途的新治疗方法.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 的发展是由涉及脂多糖 (LPS),无细胞DNA (cfDNA) 和活性氧物种 (ROS) 的级联驱动的.
- 目前的IBD治疗在向和有效性方面面临挑战.
研究的目的:
- 开发用于有效的IBD治疗的新型性纳米药物.
- 创建一个能够同时准LPS,cfDNA和ROS的多功能纳米粒子.
主要方法:
- 通过生物仿真生物化,构建聚乙胺 (PEI) -L/D-酸 (L/D-TA) 复合物模拟的半孔性有机纳米粒子 (MON) (PEI-L/D-TA@MON).
- 整合了四个功能部分:PEI用于cfDNA吸引,四硫化键用于ROS反应,西兰醇组用于LPS吸附,以及L/D-TA用于性识别和定位.
- 口服PEI-L-TA@MON用于针对炎症肠道组织的向输送.
主要成果:
- PEI-L/D-TA@MON表现出偏好的形状和与肠道粘膜的立体匹配,使其能够有效地固定在炎症部位上.
- 这种纳米药物成功地从炎症肠道中消除了LPS,ROS和cfDNA.
- 观察到氧化应激的显著缓解,抑制炎症级联,恢复免疫恒温.
结论:
- PEI-L/D-TA@MON为IBD提供了一种快速,具有成本效益和低毒性的治疗策略.
- 纳米医药的设计促进了向病变定位和多组件炎症触发器中和.
- 这些发现突显了性纳米药物在IBD治疗中的潜力,具有有希望的翻译性临床前景.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
01:29Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107